The increase in tariffs and export control actions by the Trump Administration has led to additional reporting and compliance obligations for companies that import and export goods. To ensure these new tariffs and rules are...more
Key Takeaways - The First Circuit ruled in United States v. Regeneron Pharmaceuticals, Inc., that the government must prove but-for causation to establish False Claims Act (FCA) liability based on violations of the...more
2/21/2025
/ Anti-Kickback Statute ,
Compliance ,
Department of Health and Human Services (HHS) ,
False Claims Act (FCA) ,
Healthcare Fraud ,
Life Sciences ,
Medicare ,
Pharmaceutical Industry ,
Risk Management ,
Safe Harbors ,
Whistleblowers